Announcement • Jun 26
Medx Health Corp. Launches Skinsecure Cloud-Based Saas Platform Linking Siascope Imaging Devices to Cro Workflows
MedX Health Corp. announced the commercial launch of SkinSecure, a cloud-based SaaS platform that links the Company’s native SIAscope multi-spectral imaging devices directly to Contract Research Organization (CRO) workflows. SkinSecure maps collagen, melanin and hemoglobin in living skin in a single capture, giving skin trials immediate, objective biomarker data across multiple sites and multiple subjects, with instant shared access to every result. SkinSecure is built on MedX’s patented SIAscopy technology, which powers its FDA-approved DermSecure platform and backed by more than 30 years of peer-reviewed scientific heritage. SkinSecure fits directly into established trial protocols. For collagen endpoints, it offers an alternative to expensive, invasive punch biopsies. SkinSecure maps collagen, melanin and haemoglobin in skin in around 30 seconds, without any need for biopsy. The global collagen market is valued at USD 5,200 million in 2025 and forecast to reach USD 8,700 million by 2034, at a compound annual growth rate of 5.8%. This is the entry segment for SkinSecure, spanning dermatology trials, aesthetic biostimulator studies, topical skincare validation, and MedSpa efficacy research. The non-invasive quantitative collagen measurement capacity of SkinSecure also unlocks materially-larger adjacent sectors: pharmaceutical therapeutic development (anti-fibrotic, regenerative medicine, oncology, wound healing), injectable and biologic biostimulators, ingestible and nutraceutical validation, energy-based medical devices and longevity research. Across all of them, sponsors today rely on invasive biopsy or indirect surrogate endpoints, because no direct, quantitative in vivo collagen standard currently exists. Many CRO’s already run collagen-dependent programmes without a scalable biomarker - making SkinSecure a direct workflow replacement, not a speculative use case. MedX is not entering a device category; it is establishing the quantitative standard by which skin biology will be measured in vivo across clinical research, aesthetics and consumer health. In CRO and pharmaceutical settings, collagen measurement has depended historically on punch biopsy - a procedure that carries significant cost, logistics and subject burden. Across a 200-subject, five-timepoint study, for example, direct biopsy costs can run into hundreds of thousands of dollars, before ethics coordination, site management and a potential high subject dropout rate driven by procedure refusal. SkinSecure removes that workflow for collagen endpoints, at an annual platform cost that is a fraction of a single study’s biopsy spend. For cosmetics brands and consumer research, SkinSecure adds an objective, physics-based biological measurement layer to efficacy panels that have traditionally relied on subjective grading or surface-only imaging, thereby strengthening the evidence base behind product claims. SkinSecure is built on proprietary, patented SIAscopy hardware and software. The same core technology has already been used by more than 29 CROs and sponsors worldwide to test the efficacy of their products. SkinSecure now delivers it as a cloud-based SaaS service. A single SkinSecure deployment measures four primary skin molecular components at once - collagen, melanin, dermal melanin and hemoglobin - in absolute biological units. What would otherwise require multiple instruments, multiple protocols and multiple analysis pipelines is delivered in a single non-invasive capture. No other device or platform on the market does this. Measuring melanin and hemoglobin alongside collagen creates compound endpoint value. Biostimulator sponsors capture both the collagen-induction endpoint and the vascular (haemoglobin) response needed to characterise treatment mechanisms. Beauty brands running anti-ageing studies can simultaneously measure changes in skin tone (melanin and haemoglobin) and dermal collagen - complete skin profiling, essential where claims span multiple skin tones globally. Following adoption in CRO and sponsor-led workflows, consumer applications represent the largest downstream scaling opportunity. SkinSecure is available immediately, with full commercial deployment beginning in July 2026.
